Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

994
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
994
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

601
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
601
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms.

Nature communications·2026
Same author

Loss of Y Chromosome Associates With Lung and Cardiac Dysfunction in COPD.

Comprehensive Physiology·2026
Same author

Bronchodilator reversibility, body plethysmographic phenotypes, and mortality in patients with COPD or PRISm.

The European respiratory journal·2026
Same author

Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA.

Therapeutic advances in respiratory disease·2026
Same author

Association of Obesity with Symptoms and Quality of Life in COPD: Results from COSYCONET.

International journal of chronic obstructive pulmonary disease·2026
Same author

Electrocardiogram-based detection of an atrial cardiomyopathy predicts postoperative supraventricular arrhythmias after lung transplantation.

JTCVS open·2025

Related Experiment Video

Updated: Mar 14, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.6K

[Alpha-1-antitrypsin deficiency - an update].

Nikolas Bernhard, Robert Bals, Sebastian Fähndrich

    Deutsche Medizinische Wochenschrift (1946)
    |October 5, 2016
    PubMed
    Summary

    Alpha-1-antitrypsin deficiency (AATD) is underdiagnosed but treatable. Augmentation therapy effectively slows emphysema progression in AATD patients, as shown by CT lung density.

    Area of Science:

    • Pulmonology
    • Genetics
    • Hepatology

    Background:

    • Alpha-1-antitrypsin deficiency (AATD) is an inherited disorder.
    • It is a significant risk factor for chronic obstructive pulmonary disease (COPD) and liver cirrhosis.
    • AATD is frequently underdiagnosed, leading to delayed treatment.

    Purpose of the Study:

    • To evaluate the effectiveness of Alpha-1-antitrypsin (AAT) augmentation therapy.
    • To assess the impact of AAT augmentation on the progression of emphysema.
    • To compare the sensitivity of CT lung density with FEV1 and DLCO in measuring disease progression.

    Main Methods:

    • Prospective, placebo-controlled, randomized trial (RAPID trial).
    • Inclusion of patients with AATD.
    • Measurement of emphysema progression using CT lung density.

    More Related Videos

    Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
    06:33

    Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

    Published on: June 9, 2018

    8.2K
    Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
    03:38

    Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

    Published on: June 20, 2025

    1.1K

    Related Experiment Videos

    Last Updated: Mar 14, 2026

    In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
    10:16

    In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

    Published on: December 20, 2017

    8.6K
    Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
    06:33

    Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

    Published on: June 9, 2018

    8.2K
    Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
    03:38

    Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

    Published on: June 20, 2025

    1.1K

    Main Results:

    • AAT augmentation therapy demonstrated effectiveness in slowing emphysema progression.
    • CT lung density proved to be a sensitive marker for emphysema progression.
    • Higher serum AAT levels correlated with a reduced decline in lung density.

    Conclusions:

    • AAT augmentation therapy is effective in managing emphysema progression in AATD patients.
    • CT lung density is a valuable tool for monitoring disease progression in AATD.
    • Maintaining adequate serum AAT levels is crucial for therapeutic success.